Discover
BLRX
BioLineRx Ltd.
2.96
1 x 2.91
1 x 3.03
bid
ask
+
0.04
1.54%
10:10 AM
timesize
| Ytd | 7.04% | |
| 1y | -33.96% |
2.89
day range
2.99
2.15
52 week range
4.75
| Open | 2.90 | Prev Close | 2.92 | Low | 2.89 | High | 2.99 | Mkt Cap | 12.71M |
| Vol | 8.77K | Avg Vol | 53.71K | EPS | -1.85 | P/E | -1.58 | Forward P/E | -1.06 |
| Beta | 1.55 | Short Ratio | 2.39 | Inst. Own | 3.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.14 | 200-d Avg | 3.05 | 1yr Est | 4.57 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-25 | 2024-09 | -0.08 | -0.07 | 0.01 | 12.50% |
| 2024-08-15 | 2024-06 | -0.08 | 0.01 | 0.09 | 112.50% |
| 2024-05-28 | 2024-03 | -0.29 | -0.01 | 0.28 | 96.55% |
| 2024-03-26 | 2023-12 | -0.22 | -0.15 | 0.07 | 31.82% |
| 2023-11-20 | 2023-09 | -0.18 | -0.3 | -0.12 | -66.67% |
| 2023-08-30 | 2023-06 | -0.16 | -0.3 | -0.14 | -87.50% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-29 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Alyeska Investment Group, L.p. | 866.50K | 202.24K | 1.08% |
| 2024-06-29 | CVI Holdings, LLC | 815.68K | 190.38K | 1.02% |
| 2024-09-29 | Envestnet Asset Management | 239.19K | 55.83K | 0.30% |
| 2024-09-29 | Values First Advisors, Inc. | 197.52K | 46.10K | 0.25% |
| 2024-09-29 | Morgan Stanley | 197.54K | 46.11K | 0.25% |
| 2024-09-29 | Atria Investments, Inc. | 133.97K | 31.27K | 0.17% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 39.99K | 9.33K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 40 | 2025-01-30 |
| 1 : 15 | 2019-07-15 |